Trial Profile
A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2018
Price :
$35
*
At a glance
- Drugs Edonerpic (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Toyama Chemical
- 16 Jul 2013 Primary endpoint 'Alzheimer's-Disease-Assessment-Scale-cognitive-subpart' has not been met.
- 16 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
- 22 Dec 2011 Actual patient number is 373 according to ClinicalTrials.gov.